Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
88%(7 trials)

Phase Distribution

Ph phase_2
1
11%
Ph phase_3
5
56%
Ph phase_4
2
22%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
5(55.6%)
Phase 4Post-market surveillance
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Terminated(1)

Detailed Status

Completed8
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 21 (11.1%)
Phase 35 (55.6%)
Phase 42 (22.2%)

Trials by Status

completed889%
withdrawn111%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_4

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT01957150
completedphase_3

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

NCT01313676
withdrawnphase_4

The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma

NCT03363191
completedphase_3

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02105974
completedphase_3

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

NCT01336608
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01957150Phase 4

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Completed
NCT01313676Phase 3

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Completed
NCT03363191Phase 4

The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma

Withdrawn
NCT02105974Phase 3

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT01336608Phase 3

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Completed
NCT01711463Phase 1

Relovair PD PK in Chinese Healthy Subjects

Completed
NCT02094937Phase 3

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

Completed
NCT01453023Phase 2

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

Completed
NCT01376245Phase 3

A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9